9258 Wealth Management LLC Acquires Shares of 820 Becton, Dickinson and Company (NYSE:BDX)

9258 Wealth Management LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 820 shares of the medical instruments supplier’s stock, valued at approximately $203,000.

A number of other hedge funds also recently made changes to their positions in the company. TFB Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 17.5% during the 1st quarter. TFB Advisors LLC now owns 1,410 shares of the medical instruments supplier’s stock worth $330,000 after acquiring an additional 210 shares in the last quarter. Mediolanum International Funds Ltd purchased a new stake in Becton, Dickinson and Company during the first quarter valued at $28,415,000. Callan Capital LLC lifted its position in Becton, Dickinson and Company by 2.2% during the first quarter. Callan Capital LLC now owns 7,039 shares of the medical instruments supplier’s stock valued at $1,742,000 after purchasing an additional 149 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Becton, Dickinson and Company during the first quarter valued at $252,000. Finally, Westchester Capital Management Inc. grew its stake in shares of Becton, Dickinson and Company by 5.9% in the 1st quarter. Westchester Capital Management Inc. now owns 48,152 shares of the medical instruments supplier’s stock worth $11,915,000 after buying an additional 2,690 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 0.5 %

BDX stock traded up $1.07 during midday trading on Thursday, reaching $224.94. The company’s stock had a trading volume of 1,138,396 shares, compared to its average volume of 1,430,190. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $287.32. The firm has a market capitalization of $65.01 billion, a price-to-earnings ratio of 49.31, a PEG ratio of 1.97 and a beta of 0.42. The stock has a fifty day simple moving average of $233.34 and a two-hundred day simple moving average of $237.11. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.86 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were issued a $0.95 dividend. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.69%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target for the company. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. Barclays boosted their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Citigroup lowered their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Evercore ISI cut their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $280.14.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the completion of the sale, the executive vice president now directly owns 14,608 shares of the company’s stock, valued at approximately $3,457,713.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the transaction, the executive vice president now owns 14,608 shares in the company, valued at $3,457,713.60. The disclosure for this sale can be found here. Insiders have sold a total of 8,615 shares of company stock valued at $2,033,381 over the last quarter. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.